One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

Reviving an ancient human gene that prevents gout and fatty liver disease, scientists at Georgia State University have marked a potential breakthrough in treating these metabolic conditions. Using ...

Researchers identified a CRISPR-based genetic mechanism that restrains the virulence of a key gum disease bacterium.

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

The global CRISPR technology market is anticipated to grow at a robust compound annual growth rate of approximately 16% over the next five years. This rapid expansion is driven by continuous ...

Add Yahoo as a preferred source to see more of our stories on Google. CRISPR Gene Edit Cuts Cholesterol 50% In New Trial Image by Canva A small but promising study using a type of gene-editing ...

Researchers have developed a technology that delivers RNA to damaged neurons and stimulates regrowth - paving the way for potential treatments for neurodegenerative diseases like ALS and spinal ...

The coronavirus disease 2019 (COVID-19) pandemic was one of the most serious public health calamities in the last decade, causing global morbidity and mortality in the millions. The emergence of ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.